Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Loss of HRD functional phenotype impedes immunotherapy and can be reversed by HDAC inhibitor in ovarian cancer.

International journal of biological sciences - 1 Jan 2023

Yang Dong, Huang Fu-Xue, Wei Wei, Li Qia-Qia, Wu Jun-Wan, Huang Yun, Li Zhi-Ling, Zhang Hai-Liang, Li Xuan, Yuan Qiu-Er, Chen Qing-Shan, Feng Gong-Kan, Rong Deng, Li Jun-Dong, Zhu Xiao-Feng

Abstract excerpt

In recent years, homologous recombination deficiency (HRD) has not achieved the expected substantial promotion of immunotherapeutic efficacy in ovarian cancer. This study aims to explore the role of HRD functional phenotype as a powerful biomarker in identifying HRD patients who may benefit from immunotherapy. HRD functional phenotype, namely HRD-EXCUTE, was defined as the average level of the 15 hub genes...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Histone Deacetylase Inhibitors
Share to Homologous Recombination

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Ovarian Neoplasms

Share to Phenotype

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 37063431
DOI: 10.7150/ijbs.79654
PMCID: PMC10092773

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Loss of HRD functional phenotype impedes immunotherapy and can be reversed by HDAC inhibitor in ovarian cancer.PMID 37063431Read ↗

Identification of biomarkers complementary to homologous recombination deficiency for improving the clinical outcome of ovarian serous cystadenocarcinoma.Semantic proximity Read ↗

Developing a whole exome sequencing-based homologous recombination deficiency test of epithelial ovarian cancerSemantic proximity Read ↗

Identification of biomarkers complementary to homologous recombination deficiency for improving the clinical outcome of ovarian serous cystadenocarcinomaSemantic proximity Read ↗

Whole exome sequencing-based homologous recombination deficiency test for epithelial ovarian cancerSemantic proximity Read ↗

Multiomics analysis of homologous recombination deficiency across cancer types.Semantic proximity Read ↗

Pan-cancer analysis reveals homologous recombination deficiency score as a predictive marker for immunotherapy responders.Semantic proximity Read ↗

HRDetect in Ovarian Carcinoma: Stratification and Therapeutic ImplicationsSemantic proximity Read ↗

Homologous recombination deficiency in diverse cancer types and its correlation with platinum chemotherapy efficiency in ovarian cancerSemantic proximity Read ↗

Homologous Recombination Deficiency as a Novel Therapeutic Target in Various Solid TumorsSemantic proximity Read ↗

Neoadjuvant PARPi or chemotherapy in ovarian cancer informs targeting effector Treg cells for homologous-recombination-deficient tumorsSemantic proximity Read ↗

Pan-cancer Analysis of Homologous Recombination Deficiency in Cell LinesSemantic proximity Read ↗

Genomic and molecular landscape of homologous recombination deficiency across multiple cancer typesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.